These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29153032)

  • 1. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J; Henschel C; Chou J; Lin A; Del Balzo U
    Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor.
    Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E
    Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
    Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT; Lo YC; Gao ZH; Wu SN
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.
    Mäkinen S; Sree S; Ala-Nisula T; Kultalahti H; Koivunen P; Koistinen HA
    Diabetologia; 2024 Sep; 67(9):1943-1954. PubMed ID: 38814443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
    Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
    Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
    Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
    Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H; Wang X; Zhang X; Wang H; Jiang W
    Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
    Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
    Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicology and carcinogenesis studies of N,N-dimethyl-p-toluidine (CAS No. 99-97-8) in F344/N rats and B6C3F1/N mice (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2012 Sep; (579):1-211. PubMed ID: 23027199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
    Mima A; Horii Y
    In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
    Groenendaal-van de Meent D; den Adel M; van Dijk J; Barroso-Fernandez B; El Galta R; Golor G; Schaddelee M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):685-692. PubMed ID: 29752643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
    Shibata T; Nomura Y; Takada A; Ueno M; Katashima M; Yazawa R; Furihata K
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):304-313. PubMed ID: 29966038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.